118072-93-8

Zoledronic Acid (ZOL 446) is a bisphosphonate. Zoledronic Acid (ZOL 446) is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronic Acid (ZOL 446) is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.

Zoledronic acid monohydrate (CGP 42446) is a synthetic imidazole bisphosphonate analog with anti-bone-resorption activity.

[13C, 2H2]-Zoledronic Acid, Monohydrate (Standard) is a reference standard of [13C, 2H2]-Zoledronic Acid, Monohydrate intended for quantitative analysis, quality control, and related biochemical research applications.

Zoledronic Acid (Zoledronate) disodium tetrahydrate is a potent third-generation bisphosphonate (BP) with strong anti-resorptive activity, effectively inhibiting osteoclast differentiation and apoptosis, and demonstrating anti-cancer properties [1].

Zoledronic acid-D3 is a deuterium-labeled form of Zoledronic acid (T6739). Compounds labeled with stable or radioactive isotopes are utilized in metabolic analyses to enable precise tracking and quantification of individual atom movements.

Zoledronate disodium is an inhibitor of osteoclastogenesis and macrophage recruitment, decreasing bone turnover and stabilizing the bone matrix, exhibiting diverse anti-tumor effects in osteosarcoma.